821 results about "Purine" patented technology

The invention provides an animal bifidobacterium subsp. Lactis HNU329 with uric acid reducing ability and application thereof, the animal bifidobacterium subsp. Lactis HNU329 is preserved in Guangdong Microbiological Culture Collection Center GDMCC, the preservation address is Institute of Microbiology, Guangdong Academy of Sciences, on 5th floor, No. 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the preservation number is CGMCC No: 64546. The preparation method comprises the following steps of: classifying and naming Bifidobacteria animata subsp.lactis, and carrying out classification and naming on the Bifidobacteria animata subsp.lactis. The strain has good capacity of degrading nucleoside and purine in vitro, also shows good uric acid reducing capacity and anti-inflammatory capacity in animal model evaluation, and can regulate intestinal flora of mice with hyperuricemia and improve symptoms of hyperuricemia. The traditional Chinese medicine composition has no toxic or side effect, high safety and wide application prospect.

The invention discloses a method for simultaneously detecting ergothioneine, ergosterol, ergosterol peroxide and lentinine in lentinus edodes, and belongs to the technical field of measurement of active ingredients of the lentinus edodes. The method comprises the following steps: detecting a shiitake mushroom extracting solution by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry mode, wherein a chromatographic column is an HILIC or C18 chromatographic column; the mobile phase A and the mobile phase B are an aqueous solution containing formic acid and a methanol or acetonitrile solution containing formic acid respectively; the mass spectrum conditions comprise an electrospray ionization source; a positive ion multiple reaction monitoring mode; the ion spraying temperature is 315-325 DEG C; the temperature of the ion transmission tube is 320-330 DEG C; and the ion spraying voltage is 3500 V to 3700 V. The method has the characteristics of high sensitivity, high selectivity and high accuracy, and is suitable for quantitative detection of ergothioneine, lentinine, ergosterol peroxide and ergosterol compounds in shiitake mushrooms.

The invention discloses a construction method and application of a gene modified mesenchymal stem cell. The construction method comprises the following steps: constructing a recombinant lentivirus carrying PD-L1 and ICAM1 genes; the recombinant lentivirus carrying the PD-L1 gene and the ICAM1 gene is transfected with mesenchymal stem cells, and the mesenchymal stem cells are screened by puromycin, so that an engineered mesenchymal stem cell strain modified by the PD-L1 gene and the ICAM1 gene is obtained; the mesenchymal stem cells provided by the invention are modified by engineering genes of PD-L1 and ICAM1, and are screened by puromycin to obtain a mesenchymal stem cell strain capable of stably and highly expressing the genes of PD-L1 and ICAM1; after the mesenchymal stem cells highly expressing the PD-L1 and ICAM1 genes are intravenously injected into an autoimmune hepatitis animal model, the autoimmune hepatitis symptom can be remarkably relieved, the liver injury degree can be reduced, the expression of inflammatory factors can be regulated, the inflammatory reaction can be inhibited, and the obvious curative effect can be achieved.

The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

The invention belongs to the technical field of functional microorganism screening and application, and particularly relates to a strain with a purine reducing function and application thereof. The lactococcus lactis AMCC 11671 (Lactococcus lactis AMCC 11671) provided by the invention is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number of the lactococcus lactis AMCC 11671 is CCTCC NO: M 2024078. The lactococcus lactis AMCC 11671 provided by the invention has good crude enzyme activity, can effectively slow down the generation and accumulation of uric acid by reducing the purine content and degrading uric acid, has good tolerance to acid and cholate, has the ability to tolerate gastrointestinal tract environment, and has potential of colonization in human gastrointestinal tracts and play roles.

The invention discloses a genetically engineered bacterium for producing uridine diphosphate glucose as well as a construction method and application of the genetically engineered bacterium, and belongs to the technical field of genetic engineering. The following genes are overexpressed in the genetically engineered bacterium: a pyrimidine nucleoside operon gene, a carbamyl phosphate synthetase gene, an aspartate carbamyl transaminase gene, an orotic acid phosphoribose transferase gene, a phosphoribose pyrophosphate synthase gene, a uridylate kinase gene and a glucophosphate mutase gene. A uridine triphosphate glucose-1-phosphate uridine group transferase gene; the genetically engineered bacterium does not express the following genes: a purine nucleotide repressor protein gene, a deoxyribonucleoside triphosphate reductase gene, a nucleoside triphosphate pyrophosphohydrolase gene, a cytidine triphosphate synthase gene, a pyrimidine nucleotidase gene, a nucleotidase gene, an ornithine carbamoyltransferase gene, a UDPG dehydrogenase gene and a lacI repressor protein gene. The genetically engineered bacterium can be used for efficiently synthesizing UDPG by taking glucose as a substrate.

The invention discloses lactococcus lactis subsp. Lactis and application thereof in fermentation of American cockroach powder. The strain is separated and screened from the intestinal contents of the Amolops nobilis, grows well on an MRS agar culture medium, is not hemolyzed, is sensitive to various common antibiotics, has relatively strong adaptive capacity to the intestinal environment of human and animals, has relatively strong lactic acid production capacity, and has strong inhibition capacity to common intestinal pathogens of human and animals. When the strain is used for fermenting American cockroach powder, the content of bioactive substances such as amino acids, peptides, indoles, pyrimidine and purines can be greatly increased, fermented sterile supernate has an obvious effect on mouse colitis induced by DSS, and the inflammatory factor level is remarkably reduced; the strain opens up a new way for further development and utilization of the traditional Chinese medicinal material periplaneta americana.

The invention relates to the technical field of agricultural science, and discloses a low-purine ecological pig circulating breeding system which comprises a breeding environment regulation and control module, a low-purine feed management module, an excrement treatment module, a recycling module, a health monitoring module, an intelligent decision-making module, a traceability management module, a water quality purification module and an energy recovery module. The breeding environment regulation and control module monitors in real time and automatically regulates pig house environment parameters through a distributed sensor network; the low-purine feed management module generates a low-purine feed formula based on growth stage recognition and nutritional requirement analysis; the excrement treatment module is used for converting breeding wastes into organic fertilizer raw materials; the cyclic utilization module realizes precise returning of the organic fertilizer to the field according to planting requirements; the health monitoring module evaluates the purine level of the swinery; the intelligent decision-making module integrates the multi-source data to generate a comprehensive optimization scheme; and the traceability management module records whole-process data through a block chain technology. The stability of low-purine culture is guaranteed, and the success rate of low-purine culture is increased.

The present invention discloses the application of a 1,7-dihydro-6H-purin-6-one compound in the preparation of an anti-pulmonary fibrosis drug, which relates to the technical field of biomedicine. The application of the 1,7-dihydro-6H-purin-6-one compound of the present invention in the preparation of an anti-pulmonary fibrosis drug detects the anti-pulmonary fibrosis pharmacological activity of the 1,7-dihydro-6H-purin-6-one compound after structural modification and transformation, tests the pharmacological activity of this type of compound in a variety of animal disease models, and provides data on the activity of preventing and treating different types of pulmonary fibrosis, confirming that they all have good activity, and the effect is significantly better than the clinically commonly used positive drug nintedanib, and the effect is also better than hypoxanthine analogs A, B, and C. The application of the 1,7-dihydro-6H-purin-6-one compound of the present invention in the preparation of an anti-pulmonary fibrosis drug can provide a new skeleton for the screening of new compounds for the preparation of anti-pulmonary fibrosis drugs, and lay a theoretical foundation for the development of new lead compounds.

The present invention provides a compound of Formula (I):or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).

The invention provides a perovskite solar cell, a preparation method thereof and a photovoltaic module. The perovskite solar cell comprises a first electrode, a hole transport layer, a perovskite layer, an electron transport layer and a second electrode which are stacked in sequence. The material of the hole transport layer comprises a biomolecular material which is fixed on a self-assembly monomolecular layer material through an intermolecular force, and the biomolecular material comprises one or more of guanine, adenine, thymine, uracil, cytosine, hydroxymethylcytosine, xanthine, hypoxanthine, 6-mercaptopurine and corrin. According to the perovskite cell provided by the invention, the biomolecular material with a plurality of nitrogen heterocyclic structures and amino groups is added to generate multipoint hydrogen-bond interaction and pi-pi accumulation with the tail end of the SAM, so that the orderliness of molecular arrangement is improved, and the dipole direction and strength of the whole interface are regulated and controlled; and a coordination bond or hydrogen bond network is formed by the coordination compound and uncoordinated cations or anions in perovskite, so that interface defects are effectively passivated, and the thermal stability and the humid and hot life of a device are enhanced.

The invention provides a strain of fermentation lactobacillus mucus TG017, and the strain of fermentation lactobacillus mucus TG017 has the effects of reducing uric acid, purine and adenosine. The lactobacillus fermentum is lactobacillus fermentum TG017, is preserved in the China Center for Type Culture Collection on April 10, 2023, has the preservation number of CCTCC NO: M 2023513, and is located in the preservation center of Wuhan University in Hubei China, and the preservation number of the lactobacillus fermentum TG017 is CCTCC NO: M 2023513. The invention further relates to the use of the Lactobacillus mucilaginosus TG017 strain.

The invention relates to the field of microorganisms, and discloses a Lactococcus lactis subsp. Lactis VB346 which is preserved in the China Center for Type Culture Collection on September 20, 2024, and the preservation number is CCTCC NO: M 20242013. The invention further discloses a preparation method of the Lactococcus lactis subsp. Lactis VB346. The lactococcus lactis subsp. Lactis VB346 disclosed by the invention has the capability of efficiently degrading purine nucleoside, and can decompose purine nucleoside in ingested food in intestinal tracts, so that the absorption amount of purine nucleoside by small intestines is reduced. The polypeptide has the ability of degrading bilirubin, and can be used for treating or improving hyperbilirubinemia, or improving liver and gall injury caused by hyperbilirubin; meanwhile, the acid resistance required by survival in the stomach, the cholate tolerance required by survival in the intestinal tract and the stable survival ability in the intestinal tract are achieved, and the bacillus subtilis has huge application prospects in preparation of drugs, microbial agents, health care products or food.

To provide a novel beer-flavored beverage which has a reduced purine body concentration but has good depth of flavor in the latter half, good richness and good balance.SOLUTION: According to the present invention, provided is a beer-flavored beverage which has a purine body concentration of 12 mg / 100 mL or less and which contains 0.5 ppb or more of 2-methylpyrazine and / or 0.5 ppb or more of 2,6-dimethylpyrazine. Preferably, the total content of 2-methylpyrazine and 2,6-dimethylpyrazine is 1 ppb or more.SELECTED DRAWING: None

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The invention relates to the fields of biology, medicine and clinic. In particular to application of PAICS as a target spot in developing or screening reagents for preventing and / or treating orthopoxvirus infection, and application of inhibiting a synthetic pathway of purine nucleotide and / or inhibiting a metabolic pathway of folic acid in preparing reagents for treating and / or preventing orthopoxvirus infection diseases. In order to restrain the infection of orthopoxvirus, the inventor team uses a CRISPR / Cas9 technology to carry out generic genome screening on host cells infected by orthopoxvirus, determines a host-dependent gene PAICS gene in the orthopoxvirus infection process, and verifies and clarifies the virus-dependent mechanism of the gene; in order to deal with the global continuous orthopoxvirus infection problem, the invention plays an important role in the development and screening of future related prevention or treatment drugs, and also expands the new clinical application of existing drugs including methotrexate, mercaptopurine, mizoribine and the like.

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and / or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and / or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin− and / or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and / or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and / or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

The present disclosure relates to an application of Antarctic red pigment in a preparation of drugs for treatment and prevention of hyperuricemia, which belongs to the field of biomedicine. The present disclosure studies a fermentation product of existing fungi Geomycos sp. wnf-18C or Geomycos sp. wnf-15A, and finds that the Antarctic red pigment produced by the fermentation product has good therapeutic effects on hyperuricemia induced by high purines. Thus, this pigment has application value in the preparation of drugs for hyperuricemia induced by high purine.

The invention belongs to the technical field of sensors, and relates to an array sensor based on cerium-based metal organic framework nano-enzyme and detection application of perfluoroalkyl compounds. The array sensor is a Ce-MOF triple enzyme activity array sensor and is provided with a plurality of mutually independent sensing channels; the sensing channel contains a Ce-MOF nano enzyme and a chromogenic substrate; the chromogenic substrates comprise a first chromogenic substrate, a second chromogenic substrate and a third chromogenic substrate, the first chromogenic substrate comprises 3, 3 ', 5, 5'-tetramethyl benzidine, the second chromogenic substrate comprises 2, 4-diaminophenol and 4-aminoantipyrine, and the third chromogenic substrate comprises xanthine, purine oxidase and nitrogen blue tetrazole. The MOF nano-enzyme array sensor constructed by the invention has relatively high sensitivity and selectivity in identification and distinguishing of PFASs compounds, not only can accurately distinguish single PFASs compounds, but also can perform quantitative detection, and has good response to PFASs with different concentrations.

The invention discloses targeted prebiotic plant extraction dietary powder for relieving hyperuricemia and a preparation technology of the targeted prebiotic plant extraction dietary powder, and belongs to the technical field of dietary powder.In a formula of the targeted prebiotic plant extraction dietary powder for relieving hyperuricemia, as a patented bacterial strain, the bacillus coagulans MKSWC01 can directly act on the intestinal tract environment, uric acid precursor substances generated by purine metabolism are degraded in a targeted mode, and generation of uric acid is reduced from the source; the chicory root superfine powder and the mulberry leaf DNJ extract respectively activate kidney excretion protein, inhibit the activity of glycosidase, accelerate discharge of uric acid through urine and block the path of conversion from fructose metabolism to uric acid; the celery seed flavone and the smilax glabra polysaccharide further play an anti-inflammatory role, the deposition risk of urate crystals at joints is reduced, and potential inflammatory response caused by hyperuricemia is relieved. Meanwhile, the resistant dextrin and the xylooligosaccharide serve as prebiotics, nutrients are provided for probiotics to support planting of the probiotics, the overall metabolic environment can be improved by adjusting intestinal flora balance, the pathological link of hyperuricemia is comprehensively covered, and the relieving effect is improved.

The invention discloses a rapid pathogenic bacterium identification method based on an accelerated purine metabolite SERS (Surface Enhanced Raman Scattering) spectrum, which comprises the following steps: (1) taking a pathogenic bacterium strain, pretreating, and then collecting the SERS spectrum; (2) carrying out spectrum preprocessing on the SERS spectrum acquired in the step (1), and then carrying out data division; (3) using different machine learning algorithms to establish a classification model of the pathogenic bacterium SERS spectrum, and selecting an optimal classification model by predicting accuracy; (4) separating, enriching, washing, resuspending, heating and standing a sample to be detected, and collecting an SERS spectrum of the sample to be detected; and (5) preprocessing the SERS spectrum obtained in the step (4), and inputting the SERS spectrum into the classification model established in the step (3) to obtain an identification result. The method successfully solves the problem that traditional bacteria SERS analysis needs long-time waiting, and the detection method is high in accuracy.

A compound of the structure:or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

The invention provides deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, pharmaceutical compositions, their use in inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.

The invention provides heterobicyclic-methylpurine pyridines and related compounds, pharmaceutical compositions, their use for inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.

The invention provides a method for preparing low-purine beer based on high-energy fluid mill equipment, and relates to the field of beer. Comprising the following steps: preparing clarified wort, and pumping the clarified wort into a high-energy fluid mill for treatment to obtain treated wort; the treated wort is subjected to flavor treatment and fermentation treatment, and the low-purine beer is obtained. The method is mainly based on a high-density energy input physical method, purine combined in nucleic acid in wort can be effectively released and is converted into a free state, the utilization rate of purine is increased through fermentation proliferation of yeast, and the purpose of reducing the purine content in a beer product is achieved. The production process flow is simple, the purine reduction effect is obvious, and the prepared beer is excellent in sense, rich in taste level, suitable for industrial production and wide in application prospect.

The invention relates to the field of medicinal chemistry, and particularly discloses purine compounds as well as a preparation method and application thereof. The purine compound provided by the invention is a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof: # imgabs0 #. The purine compound disclosed by the invention is designed based on a novel purine skeleton structure, and the anti-herpes simplex virus type 1 (HSV-1) activity of the purine compound is verified through an in-vitro antiviral experiment. Experimental data show that the HSV-1 median inhibitory concentration (EC50) of the series of compounds to HSV-1 is obviously superior to that of a clinical first-line drug acyclovir, and the series of compounds show better virus inhibition efficiency on the premise of keeping a similar selectivity index (SI = CC50 / EC50). The technical scheme breaks through the molecular framework limitation of the existing anti-HSV-1 drugs (such as acyclovir, famciclovir and the like), and has good clinical transformation value.

The purpose of the present invention is to provide a novel beer-flavored fermented beverage in which the purine concentration is reduced and the deterioration in flavor due to the reduction in purine concentration is improved. The present invention provides a beer-flavored fermented beverage having a purine concentration of 35,000 ppb or less, an adenosine concentration of 15,000 ppb or less, or a guanosine concentration of 56,000 ppb or less, wherein the 5-methylfurfural concentration is 10 ppb or more.

The invention belongs to the technical field of detection, and particularly relates to an orderly layered SERS (Surface Enhanced Raman Scattering) detection membrane as well as a preparation method and application thereof to detection of purine needling effect substances. The preparation method of the SERS detection membrane comprises the following steps: preparing noble metal nano-sol with different particle sizes, wherein the surface of the noble metal nano-sol is modified with a hydrophilic stabilizer; the preparation method comprises the following steps: respectively dispersing precious metal nano-sol with different particle sizes into water, then adding dispersion liquid, and after shaking, spontaneously assembling nano-particles on a gas-liquid interface to form a single-layer nano-particle film; the method comprises the following steps: transferring a nano-particle film to the surface of a flexible film, drying, transferring nano-particle films with at least two particle sizes on the surface of the nano-particle film, and drying to obtain the SERS detection film loaded with at least three layers of nano-particle films with different particle sizes, wherein the particle sizes of the nanoparticle films are sequentially reduced from outside to inside. According to the SERS detection membrane, macromolecular protein and small molecular purine in acupuncture body fluid can be separated out, and high-sensitivity and high-stability detection on the macromolecular protein and the small molecular purine can be achieved on the front face and the back face of the SERS detection membrane respectively.

The invention belongs to the technical field of medicines, and discloses an application of a small molecule compound in preparation of a product for preventing and / or treating pulmonary arterial hypertension and complications thereof. The small molecule compound is 8-[[4-(cyclopropanecarbonyl) piperazine-1-yl] methyl]-1, 3-dimethyl-7-(3-methylbutyl) purine-2, 6-diketone, and the structural formula is as shown in a formula (I): # imgabs0. The small molecule compound and pharmaceutically acceptable salts thereof have a remarkable treatment effect on pulmonary arterial hypertension and complications thereof, and can be used for treating pulmonary arterial hypertension and complications thereof. The effects of preventing and / or treating the pulmonary arterial hypertension include the reduction of right heart hypertrophy, the reduction of right ventricular systolic pressure, right heart enlargement, right heart dysfunction, pulmonary vascular remodeling, pulmonary arterial intima thickness, increase of vascular myelization, pulmonary arterial smooth muscle cell proliferation and migration, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy and the reduction of the right ventricular hypertrophy. The pulmonary arterial intima thickness and the vascular myelization level are improved, pulmonary vascular remodeling is reversed, and pulmonary artery smooth muscle cell proliferation and migration are inhibited.